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Cytomegalovirus 
I ~1012 I CMV Seroprevaience in Caieiras, soo Pauio, 
Brazil 
L.N.B. Almeida, A.L.E Yu, R.S. Azevedo, E. Massad. Department of 
Pathology and LIM 01 HC, School ofMedicine University ofS20 Paulo, 
S o  Pado, Brazil 
Objectives: To determine the seroprevalence of citomegalovirus 
(CMV) infection in an urban. community of S o  Paulo, Brazil 
Methods: Sera samples, obtained h m  a field work carried out 
during 1990 and 1991 in the city of Caieiras, a s m a l l  town in the 
outskirts of SBo Paulo City, stratified by age, were analysed for the 
presence of antibodies IgG (newborn to 39 years old) and IgM 
(newborn) against CMV by a ELISA technique. 
Results 462 samples were analysed h m  thu, sera collection for 
IgG, showing the following seroprevalence: 
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For IgM, we have found 2 newborn positive (5.3%). 
Conclusions: CMV infection is highly prevalent in early ages. 
The congenital infection is around 5%, indicating the need of pre- 
ventive action by vaccination. 
I PI013 I A Recombinant Protein-Based ELSA for IgM to 
HCMV 
J. GutiCrrez, MJ. Rodriguez, M.J. Vergara, G. PiCdrola, C. Maroto. 
Dpt Microbiology, Hospital San Cecilio, University .f Granuda, Spain 
Objective: We studied the diagnostic efficacy of a new ELISA that 
uses recombinant antigens to detect human cytomegalovirus IgM. 
Methods: One serum sample h m  each of 283 children aged 
5-2 years were studied prospectively. In all samples we investi- 
gated anti-IgM antibodies with the ELISA techniques Enzygnost 
(Behrmg), ETI-Cito (Sorin) (both based on whole viral particles), 
and OPUS (Behring) (based on recombinant antigen). A positive re- 
sult on any two or all three tests was the criterion for a true positive 
result. When only one of the tests was positive, demonstration of 
low-affinity IgG antibodies was used as the criterion for positivity. 
Results: Of the 283 serum samples, 254 (89.4%) were nega- 
tive with all three t e s ~ .  The 29 remaining samples tested positive 
with one or two of the three techniques. The diagnostic efficacy of 
Enzygnost, ETI-Cito and OPUS respectively was: sensitivity 50%, 
66.7%, 50%; specificity loo%, 95.6%, 96%; positive predictive value 
loo%, 25%, 21.4%; negative predictive value 98.9%. 99.2%, 96.2% 
The results with each of the three ELISAs Hered  widely; however, 
their dcgnostic efficacy was similar. Enzygnost was slightly superior 
owing to its higher positive predictive value. 
Conclusions: The method based on recombinant antigen was 
not found to be more effective than tesn based on whole viral parti- 
cles. 
[p10141 Development of the HCMV IgM Recombinant 
lmmunoassay on the Abbott AxSYM@ 
lmmunoassay Analyzer 
G.T. Maine', S. Brojanac', T. Gramins', B. Iriarte', J.C. Wue', 
M. Itoh', T. Lazzarotto2, A. Ripalti', M.P. L.andini2. 'Abbott 
Laboratories, Abbott Park, IL, USA, 'Dept. of Cliniclll and Experimental 
Medicine, Seaion of Microbiology, Unv. of Bologna, Bologna, Italy 
Objectives: To develop a new test for human cytomegalovirus 
(HCMV) IgM employing recombinant HCMV antigens for anti- 
body detection on the Abbott AxSYM@ Immunoassay Analyzer in- 
strument. 
Methods: There is a lack of agreement among commercial 
HCMV IgM tests due to the lack of standardization criteria for 
the crude viral lysate used in these tests whose composition is de- 
pendent on many variables and is d&icult to conaol. We are in 
the process of developing a new HCMV IgM test on the Abbott 
AxSYM@ Immunoassay Analyzer instrument. This test employs re- 
combinant HCMV antigens derived h m  portions of the following 
4 viral proteins: pp150 (UL32), pp52 (UL44). pp65 (uL83), and 
pp38 (UL80a). 
Results: Serum specimens obtained h m  random blood donors, 
pregnant women, and allograft recipients were tested with our new 
test under development and with 3 other c o m m e d  tests for the 
detection of HCMV-specific IgM. The resula with OUT new test 
were compared with the consensus of the other 3 tests and discor- 
dant samples were resolved using an HCMV IgM viral/recombinant 
antigen Western blot. 
Conclusion: The Abbott AxSYM@ CMV M immunoassay has 
good resolved sensitivity and spedcity when compared to the con- 
sensus of three commercial tests 
I PI015 I lgG Avidity in the Serodiagnosis of Primary 
A. Sensini, R. Castronari, C. Trovellesi, E Bistoni. Dpt.  E x p  Med. 
Biochern. Sci., Univ. Pmgia, Perugia, ItaZy 
Objective: To evaluate the usefulness of IgG avidity assessment in 
the Merentiation of primary Cytomegalovims (CMV) infection 
fiom reactivation or past infection. 
Methods: All sera tested were submitted to routine CMV serol- 
ogy. Sera were divided in three groups. In group A (24 serum sam- 
ples) primary mfection was defined by either the appearance of spe- 
cific IgG and IgM in patients previously seronegative, or a sigtuficant 
rise in IgG in the presence of IgM, or the association of dirucal 
symptoms and biologic alterations in the presence of IgM. Group B 
comprised 30 serum samples showing IgG and IgM without symp- 
toms or biologic alterations. Group C included 24 serum samples 
IgG positive and IgM negative. CMV IgG were determined us- 
ing an enzyme-linked immunosorbent assay (ELISA, Sorin Biomed- 
ica, Italy). CMV IgM were determined by capture ELISA (Sorin). 
For avidity assessment, sera were tested with standard CMV IgG 
test and in parallel by urea denaturation procedure (I. Med. Virol. 
1989;27:288). Avidrty index (AI) was expressed as the ratio between 
the absorbence readings after and without urea wash x 100, which 
resulted in: AI ~ 3 0 %  = low avidity = primary infection; 3650% 
= moderate avidity; 56100% = high avidrty = reinfection or past 
infection. 
Results: Groups B and C showed similar patterns while the mean 
AI in group A was sigruficantly Herent. 
Conclusions: The results stress the reliability of I& avidrty test 
in the identification of primary infection by CMV and confirm the 
poor diagnostic value of IgM in defining the stage of mfection. 
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A v i d i  of Cytomegalovirus-Specific IgG During 
Primary and Secondary Infection in 
lmmunmompetent and lmmunocompromised 
Subjects 
T. Lazzarotto, P. Spezzacatena, D. Abate, S .  Varani, M.P. Landuu. 
Department of C h i d  G. Experimental Medkine, Division of 
Microbioloa, University of Bologna, Bologna, Italy 
Objects: Primary Cytomegalovirus (CMV) infections have a clinical 
impact greater than recurrent infections or exogenous reinfections. 
CMV-spenfic IgM is a sensitive indicator of an ongoing or recent 
infection. However it is not a specific indicator of primary infection 
as it is often produced also during non-primary mfections. T h  work 
aimed at determining the utility of the determination of IgG avidity 
to discriminate between a primary and non primary CMV infection 
in both pregnant women and transplant recipients. 
Methods: The study has been carried out using a commercially 
available kit (RADIM, Rome, Italy) which determine IgG avidity 
to CMV antigens by ELISA. A total of 334 serum samples were 
used, of which 238 were sequential sera from 42 pregnant women 
and 15 transplant recipients undergoing virologically-proven CMV 
mfection and 96 were from latently infected blood donors. All the 
sera were also tested by conventional IgG and IgM-ELISA. 
Results: A low IgG avimty was detected in 88.6% of the subjects 
undergoing pr- CMV infection. Low avidity IgG persisted for 
approximately 16-18 weeks after the beginning of primary infection 
in both pregnant women and transplant recipients. A lugh IgG avid- 
ity was detected in 100% of the patients undergoing a non primary 
CMV infection. 96.9% of u d e c t e d  seropositive subjects had high 
avidity IgG directed against CMV. 
Conclusions: The determination of low IgG avidity is a sensi- 
tive and spec& indicator of primary CMV infection in both im- 
munocompstent and immunocompromised subjects which persists 
for approximately 4 months after infection. 
I PI017 I Cytomegalovirus IgM: Development of a New 
Test Containing Both Viral and Recombinant 
Proteins 
T. Lazzarotto, G.T. Maine M.C. Battista, G. Bergamini, 
A. Ripalti, S .  Brojanac ', M.P. Landini. Dept. of Clinical G. 
Experimental Medicine, Section of Microbioloa, University of Bologna, 
Italy, 'Abbott Laboratories, Abbott Park, nlinois, U S A  
Objectives: To obtain a more specific and sensitive test to detect 
human Cytomegalovirus (CMV) IgM in human sera. 
Methods: Ths novel test is based on conventional Western Blots 
(WB) with wal structural polypeptides to which purhed recombi- 
nant proteins have been added. In particular, to avoid false positiv- 
ity due to reactivity with the Herpesvirus p u p  common antigen 
which has the same MW, sigdcant portions of recombinant p150 
(ppUL32) have been added in order to confirm a positive result ex- 
clusively to viral p150. Furthermore, as non structural proteins are 
not present in the purified preparations of viral particles, a sigtllfi- 
cant portion of the most immunogenic non structural protein p52 
(ppUL44) has also been added. 
This new test was evaluated in comparison with conventional WB 
and nine commercially available ELISA kits in both latently-infected 
blood donors, and pregnant women and transplant recipients with 
ongoing HCMV infection. 
Results and Conclusions: The new test combines a hgh speci- 
ficity with a lugh sensitivity, characteristics that in combination have 
not been obtained with any of the other tests.  
A second generation of this new test is under development. In 
this new version purified viral proteins vp150, vp82, vp65, vp38 and 
vp28 as well as punfied recombinant proteins rp 150 and rp52 are 
dot blotted onto the same strip of nitrocellulose. 
[p10181 Evaluation of Five PCR Primers for the Early 
Diagnosis of Cytomegalovirus Infection in Liver 
Transplant Recipients 
J. Mendez, M. Espy, T. Smith, J. Whon, C. Paya. Division of 
Infecfious Diseases, Division of Clinical Microbiology, M a p  Clinic, 
Rochester, M N  55905, USA 
Five sets of primers directed to CMV (Hind 111-X Fragment, 406 
bp, France; IEAl gene, 438 bp, Sweden; major IEA, 370 bp, USA 
EcoRI Fragment D, 152 bp, USA; and EcoRI Fragment J, 147 bp, 
Netherlands) were evaluated for the early detection of target DNA in 
polymorphonuclear leukocytes (PML) from 21 liver transplant recip- 
ients for at least 8 weeks following transplantation. Of 148 specimens, 
primer pairs amphfjmg Hind 111-X Fragment detected CMV DNA in 
70 (sens, 94%) compared with 58 (EcoRI, D; sens, 87%), 30 @COW, 
J; sens, 75%), 21 (IEA 1 gene; sens, 32%); and 12 (ME& sens, 20%). 
Mean detection time of CMV DNA in PML prior to development 
of symptomatic infection was 17 days. Primers to the Hind 111 target 
were opdmal for early detection of CMV DNA in these patients. 
I PI019 I Utilii of PCR for Detection of CMV in 
Gastrointestinal Tract Biopsies 
L. Cardefioso, P. Vallejo, B. Buendia, J.L. Romin, R. Martin, 
M. L6pez-Brea. Hospital de la Princesa, Madrid, Spain 
Virological and histological methods are insensitive in detecting 
CMV from biopsies of gastrointestinal (GI) tract. The aim of this 
study was to know the udlity of PCR for the magnosis of CMV 
mfection in GI tract biopsies. 
Methods: We studied retrospectively 24 biopsies of GI tract (6 
esophagus, 3 stomach, 9 colon and 6 rectum) from 21 patients 
with nonspecifics GI symptoms. The biopsies were processed by 
cell culture (CC), shell-vial assay (SVA) in MRC-5 cells and routine 
hstology to detect CMV. Competitive PCR (CPCR) was realized 
amphfjmg a & p e n t  of CMV EA1 gene of 147 bp. CPCR prod- 
uct was hybridized with a digoxigenin labelled probe. CPCR of the 
samples was realized using three amounts of DNA (1 pg, 0.5 p g  and 
0.1 pg). A result of CPCR was considered positive when CMV was 
detected at least in one dilution of DNA. 
Results: CMV was not demonstrated in biopsies by CC and 
SVA. By routine histology two biopsies (8.3%), one colon and one 
rectum, were cytologically positive for CMV CMV was detected in 
15 biopsies (62.5%) &om 13 patients (62%) by CPCR, including the 
two positive biopsies by histology. Biopsies positives by CPCR were 
66.6% esophagus, 100% stomach, 33.3% colon and 83.3% rectum. 
Fourteen samples had PCR concordant results in all DNA dilutions 
(6 positive and 8 negative), 5 were positives in two reactions and 5 
were positive only in one reaction. 
Conclusions: CPCR is a rapid and sensitive method to detect 
CMV in biopsies from GI tract. The detection of CMV of ditferent 
amounts of DNA may show the load of CMV in the biopsy. 
I PI020 I Detection of Cytomegalovirus by PCR and 
A. Rodrigues, M.G. Rocha, G. Mardo, A.C. Magalhies-Santana. 
Lab. de Microbiologia, Fa. de Medicina, Univ. de Coimbra, Portugal 
Objectives: Infection with Cytomegalovirus (CMV) is common. In 
healthy immunocompetent individuals, CMV lnfection tends to be 
Monoclonal Antibodies 
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mild or asymptomatic, but CMV is a serious pathogen in immuno- 
compromised patients. A rapid and specific method for diagnosis of 
t h i s  mfection is required. 
Methods. Blood samples, urine, and amniotic fluid firom patients 
suspected of CMV infection (total samples 92) were tested by mon- 
oclonal antibodies (MAbs) and PCR. 
Results: In 53 blood samples tested by MAbs to CMV pp65 
(Clonab") eight were positive. By PCR only five were confirmed 
positive. Of the 45 negative by antigenemia, 12 were positive by 
PCR (8 of them detected by electrophoresis). The PCR of the 
others 39 samples detected 14 positives by hybridization, but five 
of them weren't visualized in gel electrophoresis. Of the 92 samples 
tested by PCR two (8.7%) were false positive in gel. 
Conclusions: PCR is more sensitive and specific than antigen- 
emia, furthermore allows longer storage period until samples pm- 
cessing. Therefore highly standardized and quantitative PCR assays 
to assess the relationship between CMV viremia and the clinical 
manifestation of CMV infection is required. 
m) Quantification of Human Cytomegalovirus 
DNA in Blood Leukocytes of Heart Transplanted 
Patients by Polymerase Chain Reaction 
V. Ghisetti, A. Barbui, S. Varetto, E Piduga, G. Marchm. Clinical 
Microbiology Laboratory, Molinette Hospital Turin, Itab 
Objectives: To quantize Human Cytomegalovirus (HCMV) DNA 
by competitive Polymerase Cham Reaction PCR)  in blood leuko- 
cytes (RvlNk) and to correlate results to antigenemia (pp65) test in 
heart transplant (HT) recipients. 
Methods: The s t u d y  was performed on 15 HT patients. Quan- 
titation of HCMV-DNA was expressed as genome equivalents 
(GE)/200.000 PMNLs. 
Results: Seven patients (pts) out of 15 experienced symptomatic 
HCMV infection (4 primary infections and 3 reactivations) and 
were treated whereas 8 asymptomatic HCMV infections were not 
treated. The mean peak levels of HCMV-DNA in symptomatic and 
in asymptomatic pts were 3.5 x lo5 GE and 6 x lo3 GE (p = 0.05) 
@p65+:460 and 24, respectively, p = 0.02)). In 4 symptomatic pts 
DNA peak preceded the one of antigenemia a mean of 11 days. 
In the other pts the two peaks were simultaneously. Single course 
of 15-21 days of gancidovir therapy caused marked decrease of 
HCMV-DNA and pp65 (mean levels after treatment: 2.5 x lo3 
GE and 82, respectively) in a l l  pts but 2 primary infected ones who 
had multiple relapses with persistent hlgh DNA levels (>-3 x lo5 
GE for 65 and 44 days) while drops in antigenemia were detected in 
the same period. 
Conclusions: Quantitative determination of HCMV-DNA in 
PMNLs correlates with pp65 test and DNA levels are sisllficantly 
higher in symptomatic than in asymptomatic infections. In most of 
the symptomatic infections DNA peak can precede the one of anti- 
genemia so that a pre-emptive therapy could be started earlier in 
these pts based on DNA results. In our experience antiviral therapy 
should be monitored more carefully by DNA levels. 
I PI022 I Human Cytomegalovirus Infection Lung 
Transplant: Evaluation of pp65 Antigen Test 
and Polymerase Chain Reaction for Eatiy 
Diagnosis 
V. Ghisetti, A. Barbui, S. Varetto, E Pittaluga, S. Baldi, 
M. Mancuso, M. Rapdho,  G. Marchim. Clinical Microbiology 
Lboratory, Lung Tramplant Unit, Molineffe Hospital, Turin, Italy 
Objectives: To evaluate pp65 test and PCR for early diagnosis of 
HCMV infection in 16 lung transplant (LT) (fivm 1994 to 1996). 
Methods: Monitoring was done by pp65 test and PCR on blood 
leukocytes (PMNLS). Bmnchoalveolar lavages PAL) and h a n s -  
bronchal biopsies (TBB) were tested for HCMV-DNA by PCR. 
Results: Ten patients @ts) out of 16 developed HCMV symp- 
tomatic infection (3 primary mfections and 7 reactivations) and 6 had 
asymptomatic reactivations. 609 PMNLs samples were examined by 
pp65 test; 364 PMNLs, 122 BALs and 35 TBBs were tested by Pcr. 
The only sigmficant differences among pts were a higher number of 
pp65 + PMNLs in symptomatic primary infections 202 f 162 than 
in reactivations (22 f 40, p = 0.002) and a longer persistence of 
HCMV-DNA in blood ftom primary infected pts than in reactiva- 
tions (p = 0.03). HCMV pneumonia was detected by histology on 
TBBs ftom 6 symptomatic pts at day 97 & 47 firom LT when the 
mean level ofpp65 + cells was 40 f 94 (range 1-290). Pcr detected 
DNA in BALs and TBBs ftom all pts with HCMV pneumonia, 
but also in BALs fivm 3 symptomatic and fivm 2 asymptomatic pts 
without HCMV pneumonia. The positive predictive d u e  of PCR 
on BAL for HCMV pneumonia was 77%. 
Conclusions: In pts at high risk for HCMV pneumonia, pp65 
test needs to be associated to a higher sensitive method hke PCR to 
detect viral sheddmg in BAL. As in our experience HCMV pneu- 
monia can be present when pp65 count is low, a m f u l  monitoring 
with pp65 test on PMNLs and with PCR on BAL for viral shed- 
ding detection is strictly recommended for an early dngnosis and 
treatment of HCMV infection. 
LP1023 1 Monitoring of CMV Infection on Allogeneic 
Bone Marrow Transplantation Patients by 
Different Diagnostic Methods 
N. Barlas ' , S. Kalayogu ', S. Tiirkogu ' , N. Is& ', A.S. Yavuz', 
G. Y h a z ' ,  D. Sargn', S. Badur'. 'Depmtment $Microbidon, 
Istanbul Medical Faculty, University $Istanbul, Istanbul, Turkey, 
'Division ofHematology/BMT Unit, Istanbul Medial Faculty, Univmity 
$Istanbul, Istanbul, Turkey 
Objectives: To monitor allogeneic bone rnarrow transplantation 
(BMT) patients for early diagnosis of cytomegalouiw (CMV) infection 
for six months following transplantation and to compare different 
diagnostic laboratory methods. 
Methods: Between November 1994 and September 1996, 23 
patients who underwent allogeneic BMT were tested for CMV in- 
fection after the transplantation weekly for the fint trimester, and 
monthly in the second trimester. pp65 detection in the periph- 
eral blood leucocytes (antigenemia assay) by indirect immunofluo- 
rescence assay (IFA) and CMV-IgM detection by ELISA, in some 
cases antigen detection in bronchoalveolar lavage (BAL) fluid by IFA 
were performed. 
Results: CMV infection is diagnosed in seven of 23 patients 
(30.4%) when laboratory test results were taken into considera- 
tion with the clinical findings. In four patients only antigenemia, 
in one patient CMV-IgM with anagenemia, and in one patient only 
CMV-IgM were detected. In one patient who had biopsy pmven 
CMV pneumonia antigen was detected only in the BAL fluid. Me- 
dian time for the onset of antigenemia was day 67 (range 37-160). 
Five patients were treated succesfidly with ganciclovir and intra- 
venous immunoglobulin (IVIG); two of them had asymptomatic 
infection with antigenemia. Two patients who had severe CMV in- 
fection ked during treatment. 
Conclusions: This s t u d y  confirms that prospective monitoring 
of BMT patients for CMV antigenemia leads to early dmgnosis of 
CMV mfection and at least two Werent laboratory methods should 
be used concurrently. Preemptive therapy with ganciclovir and M G  
could reduce mortality in transplantation patients. 
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I P1024) Quantitative CMV Antigen Determination as a 
Screening Assay of Patients with Advanced 
HIV Disease, at Risk for CMV Complications 
R. Madkdi ' , T. Lazzarotto ', I? Spezzacatena *, €? Dal Monte *, 
A. Mastroianni ' , 0. Coronado ', F. Chiodo 'Department of 
Experimental and Clinical Medicine, Division of lnfecfious Diseases, 
Univenity of Bologna, Bologna, Italy, 'Department of Experimental and 
Clinical Medicine, Division of MicrobioZoB, University of Bologna, 
Bologna, 1t.b 
Objective: To assess the clinical role of quantitative CMV antigen 
(Ag) determination in the diagnosis of HIV-related CMV infection. 
Methods: An indirect immunofluorescence assay for the quan- 
titative search of CMV pp65 Ag in polymorphonuclear leukocytes 
(PMNL) was performed as a screening procedure of HIV-infected 
patients (p) with a CD4+ cell count <lOO/yL, presenting with 
isolated fever or a clinical picture suggesting CMV disease. 
Results: During 30 months, 221 consecutive p were evaluated, 
and 39 of them (17.6%) (29 males and 10 females, aged 29 to 54 
years) showed at least 20 pp65-positive ceW2 x lo5 PMNL. Their 
severe immunodeficiency (mean CD4+ count 23.6 plusmn; 18.9 
celE/fiL) was associated with a CMV retinitis in 16 cases, and with 
visceral or disseminated CMV dsease in the remaining 23 p. The 
quantitative Ag assay showed sigtllficantly higher values in p with 
systemic CMV infection, compared to p suffering h m  retinitis 
(mean 233.2 f 118.4 vs. 132.8 f 124.6 pp65-positive PMNL./2 
f lo5 cells; p .c 0.02, Student t test). Elevated CMV Ag levels (120 
pp65-positive PMNL/2 x lo5 cells) were detected in all cases of 
symptomatic CMV disease identifed throughout the study period, 
when excluding one p with CMV retinitis. The periodic monitor- 
ing of CMV Ag carried out during the follow-up of CMV disease 
(3 to 14 months), tested remarkably useful in evaluating the response 
to antiviral treatment and in the prediction of disease recurrences, 
which occurred in 16 episodes involving 12 Merent p (out of 27 
evaluable p), although a sigmficant rise of Ag levels was not observed 
in 6 relapses occurring in 3 p with retinitis during their antiviral 
suppressive therapy. Discussion: In our experience, an elevated num- 
ber of CMV pp65-positive cells (>20/2 x lo5 PMNL.) showed a 
remarkable association with CMV disease, with a sensitivity level 
of 97.5% during the first episode, and 72.7% during relapses. The 
apparently reduced sensitivity of CMV Ag assay during recurrences 
may be attributed to the effects of the ongoing antiviral therapy, and 
the usually lower antigen levels accompanying CMV retinitis, com- 
pared with systemic disease. The use of CMV Ag assay as a screening 
test of p with advanced HIV disease allows early identification of 
CMV complications, and makes easier to i d e n e  eventual relapses, 
reduced efficacy, or apparent resistance to anti-CMV compounds. 
The adoption of a quantitative technique is expected to increase the 
specificity of the dagnosis of HIV-related CMV disease, especially 
when this etiology is high suspected, but difficult to be confirmed 
(although CMV retinitis may be associated with relatively low Ag 
levels). 
I PI025 1 Comparison of Quantitative Detection of 
Human CMV Using the Hybrid Capture System 
and pp65 Antigenemia 
M.G. Rocha, A. Rodrigues, C. Morais, G. Marfio, 
A. MagalhZes-Santana. Laboratbrio de Minobiologia da Fmldade de 
Medicina da Universidade de Coimbra, Portugal 
Objectives: Cytomegalovirus infection is 6equent and can be se- 
rious in immunosuppressed patients. There has been considerable 
interest in the development of quantitative assays for the measure- 
ment of viral load that could be used to predlct which patients may 
develop CMV disease. In this study, we compared the Hybrid Cap- 
ture System (HCS) assay with antigenemia assay for the detection 
and quantitation of CMV 
Methods: Th~rty nine blood samples f b m  immunosuppressed 
patients were tested by the Murex Hybrid Capture TM System - 
CMV DNA Assay and the antigenemia assay with a monoclonal 
antibody dxected against the CMV pp65 antigen, followed by im- 
munoperoxidase staining. 
Results: 
From the 39 samples 8 were antigenemia positive but only five 
of these were also positive by HCS. The three negative samples 
in HCS were positive in PCR but the level of positive cells in 
antigenemia was low. There were 4 positive results in HCS &om the 
31 negative samples tested by antigenemia. In this four samples three 
were positive in PCR, showing lev& of CMV genome under 4.7 
pg/ml. The agreement percentage was 82%. 
Conclusions: The Hybrid Capture System (HCS) assay provided 
a rapid, quantitative and objective measure of CMV activity in leuko- 
cytes, but the studies must continue to ascertain the correlation with 
c h c a l  disease. 
I PI026 I Isolation of Cytomegalovitus from Blood with 
J. Reina, V Fernandez-Baca, I. Blanco. virology Unit, Hospital Son 
Dureta, Palma de MaZlorca, Spain 
We performed a study of the isolation of CMV b m  peripheral 
blood PMNs with the shell-vial culture, evaluating the diagnostic 
yield provided by the use of a second vial in order to increase the 
volume of the sample inoculated and time of incubation. Each sam- 
ple was inoculated in 2 vials of the MRC-5 cell line and stained at 
24 and 72 h, respectively. Of the 247 positive blood samples stud- 
ied, 211 (85.4%) were positive in the first vial and 220 (89%) in the 
second. The results obtained were as follows: 
the Shell-Vial Culture. Technical Considerations 
Shell-vtal culture No. (% to ponnve) 
1st (24 h) 2nd (72 h) 
+ + 184 (74.5) 
- 36 (14.5) 
- 6 (2.4) 
+ Tax 21 (8.5) 
+ 
+ 
Of the total number of samples, 3% were toxic and of the positive 
samples, 10.9%. Toxicity in the first vial was 25.9% and 85.1% in the 
second (p c 0.001). The use of a second vial led to an increase in 31 
positive cultures (14.4%). The use of a second vial incubated for 72 
h leads to an increase in the percentage of isolation of CMV fiom 
peripheral blood (PMns) with a very low toxicity. 
[p1027\ Detection of Congenital Cytomegalovirus 
Infection in Chinese Newborn Infants Using 
PCR 
EJ. Tsai, C.H. Tsai, C.-T. Peng. Department ofPediatrirr, China 
Medical College Hospital, Taichung, Taiwan 
Objectives: To define the incidence of congenital CMV infection 
in Chinese population using polymerase chain reactions (F'CR). 
Methods: Altogether 1000 urine samples were collected h m  the 
nursery. All the studied newborns were essentially healthy. The urine 
was collected within three days after birth for PCR and CMV cul- 
ture. Two pairs of primers were selected, termed the LA primers 
and M E  primers were designed to amphfy a 400bp and 435bp 
sequence of CMV DNA that codes for a portion of late antigen 
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(LA) and the major immediate-early (ME) antigen of CMV, respec- 
tively. 
Results: 18 cases were found with a positive culture of CMV 
AU 18 c h c a l  isolates were 17 positive by PCR with ME primers. 
Using LA primen, there were 14 cases detected with congenital 
CMV mfection. While using both sets of MIE and LA primers 
provided a sensitivity of 94%, a specificity of 100% when compared 
with tissue culture. The incidence of congenital CMV infection in 
the Chinese population was 1.8%. 
Conclusions: (1) The incidence of congenital CMV mfection in 
Taiwan is relative high. (2) PCR is a powerful tool in diagnosis of 
congenital CMV infection. 
I PI028 I Influence of Perinatal Persistence of 
Cytomegaly on Newborn Adaptation 
0. Kostiuk. Neonafological Department, Medual Academy .f 
Postgraduate Education, Kyiq Ukraine 
Objectives: To study influence of perinatal persistence of cy- 
tomegaly (CMV) on newborn adaptation. 
Methods: 120 newborns with perinad inllammation syndmm 
underwent clinical and laboratory examination. Among the factors 
of risk infection development gynecological and extragenital compli- 
cations of pregnancy were registered. 50% of pregnant women have 
urogenital infections. The results of blood serum analysis made with 
specd test-systems show that 64.2% ofnewborns have Ig G of CMV 
Results: Perinatal virus persistence was followed by immune re- 
duction in 75% of newborns and increase of risk of bacterial infec- 
tions development. 
From the group of examined newborns 65% got sick in neonatal 
period (gneumonia, hepatitis, omphalitis, sepsis). 
Conclusion: CMV diagnosis (ELISA) w a s  determined in 4.3% 
newborns. Clinical symptoms of CMV were as follows: h e p  
atosplenomegaly, jaundise, thrombocytopenia, respiratory and neu- 
rulogical distresses. 
1 P1029 I Molecular Analysis of the HCMV Strains 
Isolated from Infected infants 
E. Augustynowicz, A. Gzyl, D. Dzierianowska. The Children's 
Memorial Health Instihrte, Department oj Clinical Microbioloa, Warsaw, 
Poland 
Objectives: To determine the frequency of reinfection and geno- 
type of HCMV strains isolated h m  mfected infants treated and 
not-treated. 
Methods: Ninety two infants aged 1 to 5 months were divided 
into two groups: one - 32 infants infected and treated with gan- 
cidovir and the second - 60 infants - not treated. Isolates were 
analyzed by PCR method using primers for the a-sequence and 
glycopmtein B (gB) HCMV genes. A-sequence of PCR products 
were visualized on agamse gels and analysed densitomerrically. Prod- 
ucts derived by gB amplification were digested with RsaI and Hinfl 
and restriction patterns were determined by polyacrylamide gel elec- 
trophoresis. 
Results: Analysis of the a-sequence products allowed us to dis- 
tingush 9 groups ranging in size from 100 bp to 350 bp suggest- 
ing considerable diversity of HCMV strains. A-sequence analysis re- 
vealed that 5 (15.6%) of treated children and 14 (18.6%) non-treated 
excreted virus of stable genotype. Twenty one (65.6%) treated and 
32 (52.5%) non-treated children excreted HCMV with different 
a-sequence product size which suggests that reinfection was caused 
by genetically distinct strains. A-sequence was not obtained in 6 
(18.8%) treated and 14 (28.9%) non-treated children. 
Conclusion: Our results suggest that in children treated with 
gancidovir, reinfection is more hquent. 
v( The Tolerability of Ganciclovir Treatment in 
Infants 
Z. Szychowska, E. Kuchar, J. Gmszka. Clinic oflnfectioous diseases oj 
Children, Medical University .f Wroc&iu, Poland 
Objective: evaluation of the tolerabhty of gancidovir (Gr) in in- 
fants. 
Methods: 16 infants aged 3 weeks-8 months with symptomatic, 
active CMVinfection (diagnosed by presence of IgM anti-CMVand 
pp65 antigen in urine epithelial cells and/or blood leucocytes). Gan- 
ciclovir was a h t e r e d  in 1-hour intravenous infusion in a dosis 
of 7.5 mg/kg every 12 hours (in 3 children 5 mg/@ for 7 4 5  days. 
Intravenous polyvalent immunoglobulins were also admioJstered in 
12 infants. 
Results: No clinical symptoms of adverse reaction were observed 
in 15 of 16 mated infants. In one with pneumonia we observed an 
episode of food aspiration with dyspnea, cyanosis and 1-day fever. 
We found in blood eosinophilia in 8, grandocytopenia below 1.0 
G/1 in 6, leucopenia below 5.0 G/1 in 3 and anaemia in 2 children 
of 16 treated. We obsexved a moderate growth of amino@ansferases 
(AST, ALT) activity in 2 chlldren. Adverse reactions were transitory 
and reversible - discontinuation of Gr therapy was not necessary in 
any child. Single dosis of GCSF (Neupogen) with good hemato- 
logic response was given in 2 children. We noticed beneficial ef- 
fect of Gc treatment in most of the mfants (improvement of initial: 
hepatitis, hyperbilirubinemia, anaemia, leucopenia, granulocytope- 
nia and thrombocytopenia). 
Conclusions: Infants tolerate gancidovir treatment well. Adverse 
reactions (mainly bone marmw suppression) are transitory, reversible 
and do not necessitate in Gr therapy discontinuation. 
m1 Potential Value of Interferons and Antiviral 
Drugs in the Infection of Monocytic-Like Cells 
with Human Cytomegalovirus (HCMV) 
A.S. Delannoy I ,  D. Hober I ,  A. Bouddi ', F! W a d  '. 'Laboratoin 
de Virologie, C.H.U Lille, France, 'LFB, Lille, France 
Objectives: We developed the monocytic-like cell line THP-1 as a 
model to study the effects of antiviral molecules on these cells. 
Methods: We designed experiments to study the replication of 
the virus in PMA (phorbol 12-myristate 13-acetate) treated THP-1 
cells exposed to cytokines: IFN o! (interferon alpha); IFN y (inter- 
feron gamma) alone or in combination with antiviral drugs: DHPG 
(gancidovir), PFA @hosphonoformic acid) before or after incuba- 
tion with cell kee-supernatant of Towne CMV strain infected fi- 
broblasts MRC-5. Supernatants were collected and they were added 
to fibroblast culture. The infection of the fibroblasts was studied 
on the basis of immune detection of wal immediate early antigens 
(IEA) in nucleus 24 h after culture. 
Results: Incubation of PMA-treated THP-1 cells with IFN a 
(0.5 to 500 U/ml) or IFN y (0.02 to 2 ng/ml) alone prior to the in- 
fection clearly reduced virus plaque formation in a dose-dependent 
manner up to 85 f 6.5% with 500 U/ml IFN (Y and 70 f 10% with 
2 n g / d  IFN y (n = 2). However, the addition of I F N s  after infec- 
tion showed a little antiviral effect (15% inhibition with 500 U/ml 
IFN o! and no inhibition with 2 n g / d  IFN y).  The combination 
of IFNs with DHPG for 24 h at 37" C after infection had a syner- 
gistic effect. Indeed we obtained 40 f 5% inhibition with 11.1 /IM 
DHPG alone and no inhibition with 5 U/ml I F N  (Y nor with 0.2 
n g / d  IFN y whereas we obtained 65 f 4% irhbition with 11.1 
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pM DHPG combinated with 5 U / d  IFN (Y and 95 f 5% inhibition 
with 1 l . lpM DHPG in combination with 0.2 ng/d IFN y (n = 3). 
Conclusions: IFN (Y and IFN y decrease HCMV infection in 
monocytic-like cell line THP-1 and may lead to an improvement of 
the available chemotherapy against this important human pathogen. 
Combination of IFNs with DHPG after lnfection showed a syner- 
gistic effect. 
I P103q Activity of Penciclovir (PCV) in vitro against 
Cytomegalovirus (CMV) Wild Strains (WS) and 
against Strain AD169 
B. Hostettler, E? Jordan, G. Cathomas, R. Attenhofer, E? Reusser. 
University Hospital, &el, Switzerland 
PCV has a well-documented inhibitory activity against herpes sim- 
plex virus and varicelia-zoster virus. By contrast, data on its activity 
against CMV are limited. We evaluated the in vim activity of PCV 
against 3 CMV WS (#1 and #2 from marmw transplant recipients, 
#3 from a neonate) and against CMV s t r a i n  AD169, and compared 
the results with those obtained in parallel with acyclovir (ACV), 
ganciclovir (GCV), and foscarnet (FOS). A plaque reduction assay 
was used to determine the mhibitory drug concentration reducing 
plaque numbers by 50% (IC50). The drugs were tested in 6 human 
fibroblast cell lines. The results were as follows: 
Me& (nnge) 1c50 in pM 
WS#I WS#2 WS#3 C M V  AD169 
PCV 182 (13P188) 232 (5S266) 87 (72-102) 101 (68-118) 
ACV 45(29-68) 31 (18-54) 26 (24-27) 40 (28-56) 
GCV § 3 (2.65) 2 (1-3) 3 (1-5) 
FOS 75 (4S114) 73 (47-116) 106 (72-140) 75 (58-119) 
Median ICsg of 13 p M  (630) indxatmg a rerkunce to ganclclovlr. 
The pooled ICsos of PCV (all CMV strains) were significantly 
higher than those of ACV, GCV, and FOS (P < 0.0001 for each 
comparison). However, the ICs0 values obtained must also be con- 
sidered in the context of the pharmacokinetic and toxicologic prop- 
erties of the drugs tested, and the activity of PCV against CMV 
should be further investigated in vivo. 
Viral infections in solid transplant patients 
I P1033 I lnfection in Immunosuppressed Patients after 
Bone Marrow Transplantation (BMT) 
V. Tchebotkevitch, S. Moiseev, K. Abdoulkadirov. Russian Incfifute 
of Haemofology nnd Ezrnjhsiology, Sf-Petersbutg, Russia 
Twelve patients with different forms of haematological malignancies 
underwent autologous (n = 6) or allogeneic (n = 6) BMT were 
tested. The materials (blood sera and nasal swabs) were collected 
each 2 weeks during 6 months in pre- and post-transplantation pe- 
riod. Nasal swabs were washed with l ml PBS and the material was 
subjected to sedimentation. The sedimented nasal epithelium cells 
were used for direct immunofluorescence (IF) microscopy, which 
was performed with fluorescein-conjugated antibodies (Abs) to res- 
piratory viruses and Mycoplatma pneumoniae (Mp). The supernatant 
was used for detection of mucosal Abs. The detection of these Abs 
as well as Abs in blood sera was performed in Indirect Haemag- 
glutination Test (IHA) with viral (Injuenra fypes 1, 2 and 3, Aden- 
ovinrs, Rezpirntory syn6tial virus, Coronavincc) and Mp antigens. Bacte- 
rial and fungal infections were diagnosed microbiologically In all 56 
episodes of infection were diagnosed. In 54 of these episodes mixed 
Mp-viral infection was demonstrated. Twenty five (45%) episodes 
were detected in immunosuppressed patients during the period of 
profound neutropenia immediately after BMT. The clinical mani- 
festations of invasive bacterial infections caused by Eschm’chia coli, 
Mebsiella pneumoniae and Pseudomom amginosa were more severe 111 
the episodes of preexisting respiratory viral- Mp infection. So the 
viral-mycoplasmal respiratory infection decreases the resistance to 
bacteria in immunosuppressed patients. The immune response in the 
patients was characterized by dramatic decrease in blood Abs level 
whereas the mucosal Abs changed similarly to those in immuno- 
competent patients. We conclude that viral-mycoplasmal infection 
enhances the immunodepression in immunosuppressed patients es- 
pecially the general immune response rather than the local one and 
these infections must be caremy controlled. 
1-1 CMV Management to Prevent Related Allograft 
Deterioration 
U. Jacobs, D. Niese, H.-U. Klehr. Medical Dept, Univenify Hosp, 
Bonn, Germ 
Objectives: Enhanced allogenity by CMV may induce acute rejec- 
tions as well as chronic transplant (TP) damage via endothelial and 
mitogenic lesions. 
Methods: In a subset of 113 renal allografted patients (P) we 
analysed CMV incidence, onset, risk profile and evaluated earliness 
and sensitivity of cytoimmunological (lymphocyte subsets by FACS) 
and viral diagnostic work-up weekly after TX (pp65-early antigen 
(EA) (+ PCR) + CMV-IgM-titer (ELJSA techn.) + virus isolation 
in urine and throat swab), as well as the impact of early virustatic in- 
tervention on acute and long-term TP function and suMval. CMV 
disease defined as combination of one viral parameter plus organ 
deterioration. 
Results: Incidence of CMV disease was 31% posttransplant, 58% 
of all associated with monoclonal antibody therapy (OKT3) for acute 
rejection. Independently of recipient status pretransplant positive 
donor CMVIgG increased risk of disease up to 70%. In addition 
to earliness diagnostic sensitivity of CD4/CD8 inversion (93%) was 
> pp-65 early antigen (56%) > IgM seroconversion (33%) > virus 
isolation (10%). In P with recurrent CMV disease PCR was more a 
marker for lnfection regardless of disease. Leucocytes decreased from 
8.6 f 1.4 to 4.2 f 1.8/nl. Clinally the predictive value of a charac- 
teristic nocturnal hyperhidrosis all P with CMV disease complained 
about was accompanied with the CD4/CD8 inversion-decrease of 
CD4-lymphocytes and increase of CD8-lymphocytes resulting in a 
ratio <1-even preceding acute organ deterioration. The degree of 
inversion reflected severity of CMV disease course and the diagnostic 
value of this parameter was not impaired even in P on monoclonal 
antibodies. Consequent virustatic therapy contributed to improve- 
ment of transplant function with decrease of serum-creatinine &om 
3.2 f 1.2 to 1.6 f 0.5 mg/dl. There were no adverse effects associ- 
ated with ganciclovir and no drug resistance. One year graft suMval 
was improved up to 97% without any CMV complication. Statistical 
analysis after 2.7 f 1.2 yrs follow-up period excluded any remaining 
impact of previous CMV disease on longterm TP function (actuarial 
creatinine and proteinuria). 
Conclusions: Despite high incidence and varying time of on- 
set esp for primary CMV posttransplant adequate CMV monitoring 
guarantees earliest diagnosis. The trias of symptoms: CD4/CD8 in- 
version, nocturnal hyperhidrosis and leucocyte decrease are reliable 
and most sensitive predictors. Consequent virustatic treatment con- 
mbutes to impressive amelioration of transplant suMval and even 
prevention of long-term graff damage as it might result h m  unde- 
tected CMV disease on a chronic base. 
